THE BOARD OF DIRECTORS OF DIASORIN S.P.A. APPROVES THE CONSOLIDATED RESULTS FOR THE THIRD QUARTER OF 2014: INCREASE IN REVENUES AND PROFIT, STRONG FREE CASH FLOW AND SOLID NET FINANCIAL POSITION

DiaSorin (FTSE Mid Cap:DIA) is proud to announce the launch of its novel 1,25 Dihydroxyvitamin D assay for the quantitative determination of 1,25 Dihydroxyvitamin D levels in human serum and plasma, available on the LIAISON XL analyzer for the market outside the US only.

 

Dialog

New communication area.
To download technical Assays information

Download the DiaSorin App

close
Android Iphone